🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

If you are in Australia, you can and test drive the Fluicell Biopixlar AER #bioprinter at the upcoming Ausbioprint conference on Nov 20/21 at @UTSengage organised by @Carmine_3DHeart #bioprinting #MedicalResearch

We are pleased to be showcasing our #bioprinting portfolio at #Ausbioprint workshop organised by Carmine Gentile UTS Learn more bit.ly/40SyfO4 #bioprinter Fluicell @REGENHU Poietis @UpNano @BMF3D #regenerativemedicine

Researchers at Children's Hospital have created a stem cell-based neuron model to study genetic causes for epilepsy. In their work, they used BioPen together with the model to discover compounds with the ability to restore neuron function. Read more 👇 fluicell.com/researchers-cr…

We are super excited to finaly be able to present our new visual and our tissue therapeutic platform Nexocyte which together solidifies or vision to tranform how we treat disease. Read more on of fresh new home! 👉fluicell.com

We are pround to be working together with the talented and innovative team at ConScience to push the boundaries in microfluidic device fabrication and look forward to following their many exciting projects going forward.

We are happy to announce that we have received positive results from the in vivo study that we initiated in December. In the study we evaluated the implant designs and manufacturing processes used in our type 1 diabetes tissue therapeutics program. 👉fluicell.com/news/fluicell-…

Take the opportunity to listen to Fluicell's CEO talk about our many ongoing projects and what our plans are for the future. After the presentation, there will be opportunities to ask questions to Carolina. Sign up 👉 us02web.zoom.us/webinar/regist……(presentation in 🇸🇪)

Researchers at Bionomics Limited have discovered a new compound with potential for treating anxiety- and stress-related disorders. In their study, the researcher used Dynaflow Resolve to perform electrophysiology assays. Read more 👇 fluicell.com/news/researche…

The Biopixlar station at Maastricht University just received an upgrade. With the latest version of the bioprinting platform and a brand new Erlab H-Box biosafety cabinet, we are ready to make new discoveries! Fluicell MERLN Erlab #bioprinting

Fluicell’s technologies have played a key role in many discoveries and scientific breakthroughs across multiple different research areas. Step into our world of discovery and explore Fluicell's publication library: fluicell.com/platform/publi… #bioprinting #research #singlecell

🚀Haylie Helms of OHSU Knight Cancer Institute is using Biopixlar to create tumor models with single-cell precision and is presenting her work at the AACR meeting in San Diego today. We took the opportunity to speak to Haile about her research. 👉fluicell.com/news/my-favori…

We are excited to announce that we have entered a collaboration with Cellectricon, a leading drug discovery service provider, to validate our Nexocyte tissue models using key research workflows. Read more about the collaboration 👇 fluicell.com/news/fluicell-… #bioprinting

💡How do cells regulate carbon metabolism? In a recent study, researchers at Chalmers University of Technology show that yeast cells control carbon source use by altering the subcellular protein localization in response to changes in their environment. 👇 fluicell.com/news/cells-use… #singlecell

Meet Aleksandra Rak-Raszewska, postdoctoral scholar and stem cell expert at Maastricht University. We spoke to Aleksandra about the value of collaboration in research and how she discovered her passion for science when studying frogs as a child. 👉 birdieproject.eu/2024/07/01/bir…

Fluicell is developing tissue-based type 1 diabetes therapeutics based on our Nexocyte platform technology. Today, we spoke to our CTO Gavin Jeffries about how development is progressing and what makes Fluicell's therapeutic solutions stand out. 👉fluicell.com/news/engineeri…

BIRDIE is a marriage between technical innovation and groundbreaking biological science. We spoke to Niek Welkenhuysen at Fluicell about the importance of letting the needs of researchers drive technology development. Read his thoughts here: birdieproject.eu/2024/09/04/bir…

⭐️BIO-Europe is just around the corner and we are excited to explore how we can collaborate to transform the way we treat diseases. Connect with us to learn more about our tissue-based solutions for drug screening and regenerativ medicine. 👉fluicell.com/news/fluicell-… #bioeurope

❤️We are providing a wide range of human tissue solutions based on our Nexocyt platform to build the future of cardiac health. Discover more about our ongoing work to advance drug development and to make caridac repair possible. 👉fluicell.com/pipeline/heart…

More than 100 years after the discovery of insulin, type 1 diabetes remains a chronic disease that requires lifelong daily management. A special issue looked at the advances that have expanded researchers’ grasp of this disease. Learn more on #WorldDiabetesDay: